Autoimmune & ArthritisResearch PaperPaywall

Upadacitinib Misses Primary Endpoint in Takayasu Arteritis Phase 3 Trial but Trends Toward Fewer Relapses

In a 59-patient phase 3 trial, the JAK inhibitor upadacitinib did not meet its primary endpoint in Takayasu arteritis, though relapses trended lower.

Wednesday, November 18, 2026 0 views
Published in Lancet Rheumatol
A rheumatologist reviewing a CT angiogram of the aorta on a monitor beside a patient in a clinic exam room

Summary

Takayasu arteritis is a rare inflammatory disease of the large arteries, including the aorta, that mostly affects young and middle-aged women and often requires long-term steroids. This phase 3 trial tested upadacitinib, an oral JAK inhibitor that dampens inflammatory signaling, in 59 patients who had relapsed while tapering steroids. Patients took upadacitinib 15 mg or placebo daily while steroids were tapered. Relapses occurred in 37% on upadacitinib and 62% on placebo, and median time to relapse was about 108 weeks versus 20 weeks. Yet the hazard ratio of 0.52 had a confidence interval that crossed 1 (0.24-1.12), and the trial formally did not meet its primary endpoint. Serious adverse events were more numerous with upadacitinib (nine versus four), with no deaths. The results are suggestive, not conclusive, and this summary is based on the abstract only.

Detailed Summary

Takayasu arteritis is a rare inflammatory disease of the aorta and its major branches. It can narrow or weaken vessels and cause ischemic damage to the brain, heart and limbs. Most patients are young women, and treatment relies heavily on glucocorticoids, whose long-term toxicity (bone loss, metabolic and cardiovascular harm) erodes healthspan. Steroid-sparing options that maintain remission are a clear unmet need.

SELECT-TAK tested upadacitinib, an oral JAK inhibitor that blocks cytokine signaling through the JAK-STAT pathway thought to drive vascular inflammation. It was a multicenter, double-blind, randomized, placebo-controlled phase 3 trial at 31 centers in six countries. Fifty-nine patients in remission who had previously failed steroid tapering were randomized 1:1 to upadacitinib 15 mg daily (n=30) or placebo (n=29), all undergoing a steroid taper from week 4. The primary endpoint was time to first relapse.

The primary endpoint was not met. The hazard ratio was 0.52 (95% CI 0.24-1.12), with a log-rank p=0.045 that the authors did not treat as meeting the prespecified threshold. Median time to relapse was 107.9 weeks with upadacitinib (95% CI 20.1-not estimable) versus 20.1 weeks with placebo. Relapse events occurred in 11 of 30 patients (37%) on upadacitinib and 18 of 29 (62%) on placebo. Nine serious adverse events were reported with upadacitinib and four with placebo. There were no deaths, and no new clinically meaningful safety events were identified.

The direction of effect favors a role for JAK inhibition in refractory disease, and the authors call for further study. The results do not establish efficacy or support changing practice, and a mechanism-level signal on inflammatory signaling is not confirmed by a formal win.

Caveats are substantial. The trial was small, with wide confidence intervals, and the sponsor was AbbVie, with several authors employed by it. Ninety percent of participants were women, and most were Asian. This summary draws only on the abstract, so secondary endpoints, steroid exposure and detailed safety data were unavailable.

Key Findings

  • Primary endpoint of time to first relapse was not met: hazard ratio 0.52 (95% CI 0.24-1.12).
  • Relapse occurred in 37% (11/30) on upadacitinib versus 62% (18/29) on placebo.
  • Median time to relapse was 107.9 weeks with upadacitinib versus 20.1 weeks with placebo.
  • Serious adverse events: nine with upadacitinib versus four with placebo; no deaths in either group.
  • Authors judged the results numerically favorable and warranting further study in refractory disease.

Methodology

Multicenter, double-blind, randomized (1:1), placebo-controlled phase 3 trial at 31 centers in six countries, enrolling 59 patients with Takayasu arteritis in remission after relapse. Participants received upadacitinib 15 mg daily or placebo with a protocolized glucocorticoid taper. The primary endpoint was time to first relapse using a composite clinical definition.

Study Limitations

This summary is based on the abstract only. The trial was small (n=59) with a wide confidence interval, a sponsor-run design and a population that was 90% female and mostly Asian. Secondary endpoints, steroid-sparing data and detailed adverse event breakdowns were not available, and the imbalance in serious adverse events (nine versus four) is hard to interpret at this size.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: